In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
|Videos|November 4, 2021
Identifying Carcinoid Crises in Patients With Neuroendocrine Tumors Undergoing Operation
Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses his presentation at the 2021 NANETS Virtual Symposium on a prospective study of carcinoid crisis with no perioperative octreotide.
Advertisement
Pharmacy Times interviewed Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, on his presentation at the 2021 NANETS Multidisciplinary NET Medical Virtual Symposium discussing a prospective study of carcinoid crisis with no perioperative octreotide.
During the interview, Pommier explained what a carcinoid crisis is and how might it present in patients.
Advertisement
Related to this article
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
5